MedPath

Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis

Phase 3
Withdrawn
Conditions
Hemoptysis
Interventions
Drug: tranexamic acid, placebo
Registration Number
NCT01167764
Lead Sponsor
Seoul National University Hospital
Brief Summary

Hemoptysis is one of the serious complication of many pulmonary diseases. Upto now, there is no proven medical treatment in recurrence of hemoptysis. The investigators will conduct a randomized, placebo controlled trial of tranexamic acid, which can reduce the recurrence of hemoptysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • age: >=20 and <=75
  • ER visit or admission for hemoptysis
  • no evidence of hemoptysis on screening
Exclusion Criteria
  • anticoagulation treatment
  • Cr >= 2.0 mg/dL or urinary protein >= 2+ or who received renal replacement treatment
  • hepatic failure: total bilirubin >= 1.5 mg/dL or AST or ALT >= 1.5 of upper normal limit level
  • hypersensitivity to tranexamic acid
  • pregnant woman
  • fertile female who don't use contraception

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
tranexamic acidtranexamic acid, placebotranexamic acid 250mg po 3 times/day for 1 months
placebotranexamic acid, placeboplacebo po 3 times/day for 1 months
Primary Outcome Measures
NameTimeMethod
the proportion of recurrence of hemoptysis6 month: 1months medication + 5months observation
Secondary Outcome Measures
NameTimeMethod
time to recurrence6 month: 1months medication + 5months observation

Trial Locations

Locations (3)

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul Metropolitan Government Seoul National University Boramae Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath